
Podcast #245 · 1 Jul 2025
Intravesical Therapies for Intermediate Risk Bladder Cancer
- Medical Oncology
- Transurethral Resection of Bladder Tumor (TURBT)
- Urologic Oncology
- Non-Muscle Invasive Bladder Cancer (NMIBC)
- Intravesical Therapy
- Bladder Cancer
With BCG in short supply and recurrence rates still high, the race is on for better intravesical options. In this episode of BackTable Tumor Board, Dr. Lindsey Herrel, urologic oncologist at the University of Michigan, joins Dr. Ruchika Talwar to explore the evolving landscape of intravesical therapy for intermediate risk bladder cancer.
This podcast is supported by an educational grant from UroGen Pharma.
Timestamps
More about this episode
The doctors break down the nuances of defining this risk category and the clinical gray zones that complicate treatment decisions. Dr. Herrell shares her patient-centered approach to surveillance and therapy, and introduces promising new agents, including Anktiva, UGN-102, and the gemcitabine-releasing TAR-200 "pretzel" device. The discussion also highlights how advances in molecular profiling are reshaping care strategies. This episode underscores the urgent need for clearer guidelines and continued innovation to improve outcomes and quality of life for patients with this nuanced disease subtype.

